LivaNova to Present Scientific Data on VNS Therapy for Difficult-to-Treat Depression at 4th International Brain Stimulation Conference
“Many patients around the world live with major depressive disorder or bipolar disorder and continue to suffer with depressive symptoms despite traditional treatments,” said
- “Vagus Nerve Stimulation in Patients Receiving Maintenance Therapy with Electroconvulsive Therapy: A Series of 10 Cases.” Presented by Dr.
Scott T. Aaronson, Director, Clinical Research Programs, Sheppard Pratt Health System, Baltimore, Maryland, on Tuesday, December 7from 12:30 to 1:45 p.m.Eastern.
- “A prospective, multi-center randomized, controlled, blinded trial of vagus nerve stimulation for difficult-to-treat depression: A novel design for a novel treatment.” Presented by
Bryan Olin, Ph.D., Senior Vice President of Clinical, Quality Assurance and Regulatory Affairs at LivaNova, on Wednesday, December 8from 12 to 1:30 p.m.Eastern.
- “Chronic Vagus Nerve Stimulation Significantly Improves Quality of Life in Treatment-Resistant Major Depression.” Presented by Dr.
Charles Conway, Director of the Washington University Resistant Mood Disorders Center, Washington Universityin St. Louis School of Medicine, St. Louis, Missouri, on Thursday, December 9from 12 to 1:30 p.m.Eastern.
- “The effects of vagus nerve stimulation on the course and outcomes of patients with bipolar disorder in a treatment-resistant depressive episode: a 5-year prospective registry.” Presented by
Mark Bunker, LivaNova Consultant, on Thursday, December 9from 12 to 1:30 p.m.Eastern.
- “Research challenges in chronic diseases: difficult-to-treat depression.” Presented by Dr.
A. John Rush, Professor Emeritus, Duke-National Universityof Singapore, Singaporeand Adjunct Professor at the Departments of Psychiatry, Duke University Medical School, Durham, North Carolinaand Texas Tech University, Health Sciences Center, Permian Basin, on Thursday, December 9from 12 to 1:30 p.m.Eastern.
About VNS Therapy for Depression
The VNS Therapy System, Symmetry®, is indicated in the
Safe Harbor Statement
This news release contains “forward-looking statements” concerning our goals, beliefs, expectations, strategies, objectives, plans and underlying assumptions and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, statements regarding participation in upcoming events and VNS Therapy for difficult-to-treat depression. Actual results may differ materially from those indicated in our forward-looking statements as a result of various factors, including those factors set forth in Item 1A of our Annual Report on Form 10-K for the year ended
LivaNova Investor Relations and Media Contacts
Senior Director, Investor Relations
VP, Corporate Communications